Elena C. V.
- Country
- Spain
- Department
- Neurology
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Phase 2a Randomized Double‑Blind Placebo‑Controlled Study of Empasiprubart IV Monotherapy in AChR‑Ab Seropositive Generalized Myasthenia Gravis
- Phase 3 Randomized Quadruple-Blind Study on Batoclimab Efficacy and Safety in Adult Generalized Myasthenia Gravis Patients
Data & Insights
Has run more than one trial at 42 of 96 partner sites.
Specializations
Neuromuscular Disorders
This investigator specializes in the study of generalized myasthenia gravis (gMG), with particular emphasis on both antibody-positive and antibody-negative variants of the condition.
- Acetylcholine receptor antibody seronegative gMG
- AChR antibody-positive gMG
- Daily living activities assessment in gMG
Their research encompasses comprehensive evaluation of patient functionality and symptom management in myasthenia gravis.
Immunotherapy Approaches
The investigator focuses on novel therapeutic interventions using targeted immunological treatments for neuromuscular conditions.
- FcRn antagonist therapies
- Complement pathway inhibition
- Combination immunotherapy strategies
Their work includes evaluation of various dosing regimens and administration routes for immunological treatments.
Clinical Innovation
The investigator explores innovative therapeutic agents for neuromuscular disorders, including:
- Efgartigimod administration protocols
- Nipocalimab efficacy studies
- Zilucoplan long-term outcomes
- Batoclimab treatment approaches
Their research extends to both induction and maintenance therapy protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.